Compare Merck & Co., Inc. (MRK) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Zillow Group Inc Class C — how do they compare? Merck & Co., Inc. trades at $145.12 (market cap $351.28B), while Zillow Group Inc Class C trades at $28.84 (market cap $6.59B). The key difference: Merck & Co., Inc. is far larger — about 53.3× Zillow Group Inc Class C's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Zillow Group Inc Class C for 39 Days on average.
| MRK | Z | |
|---|---|---|
Market Cap | $351.28B | $6.59B |
Volume | 7,969,665 | 9,134,294 |
Sector | Health | Media |
52-Week High | $156.43 | $78.04 |
52-Week Low | $82.49 | $27.13 |
Typical Hold Time | 98 Days | 39 Days |
Enterprise Value | $398.04B | $6.47B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Zillow Group (Z) trades at $28.65, up 5.02% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported revenue of $2.58 billion in 2025, turning a net profit of $23 million after a loss in 2024, and shows improving margins. Recent news highlights AI integration in real estate and resolution of an FTC lawsuit, while the housing market faces affordability challenges.
The outlook is cautiously optimistic with a consensus price target of $60.33, implying significant upside, but risks include sensitivity to mortgage rates and competitive pressures. Earnings have beaten expectations in two of the last three quarters, supporting growth potential amid a volatile housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
